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Abstract
The use of tyrosine kinase inhibitors (TKIs) requires the testing for hot spot mutations of the molecular effectors
downstream the membrane-bound tyrosine kinases since their wild type status is expected for response to TKI therapy. We
report a novel assay that we have called Allele Specific Locked Nucleic Acid quantitative PCR (ASLNAqPCR). The assay uses
LNA-modified allele specific primers and LNA-modified beacon probes to increase sensitivity, specificity and to accurately
quantify mutations. We designed primers specific for codon 12/13 KRAS mutations and BRAF V600E, and validated the assay
with 300 routine samples from a variety of sources, including cytology specimens. All were analyzed by ASLNAqPCR and
Sanger sequencing. Discordant cases were pyrosequenced. ASLNAqPCR correctly identified BRAF and KRAS mutations in all
discordant cases and all had a mutated/wild type DNA ratio below the analytical sensitivity of the Sanger method.
ASLNAqPCR was 100% specific with greater accuracy, positive and negative predictive values compared with Sanger
sequencing. The analytical sensitivity of ASLNAqPCR is 0.1%, allowing quantification of mutated DNA in small neoplastic cell
clones. ASLNAqPCR can be performed in any laboratory with real-time PCR equipment, is very cost-effective and can easily
be adapted to detect hot spot mutations in other oncogenes.
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Introduction
Molecular therapy targeting transmembrane receptor tyrosine
kinases with a variety of tyrosine kinase inhibitors has become part
of the standard treatment for many patients with common forms of
cancer. Evidence of both tyrosine kinase activation and lack of
activating mutations in the tyrosine kinase downstream effectors is
expected as a general precondition for successful patient treatment
[1]. Among transmembrane tyrosine kinases the EGF receptor
(EGFR) is one of the main therapeutic targets since it is active in
both colorectal (CRC) and non-small cell lung cancers (NSCLC).
The MAP kinase (MAPK) signaling cascade is a mainstream
pathway that modulates many cell functions (e.g. proliferation,
differentiation, apoptosis) following the activation of tyrosine
kinase receptors like EGFR. KRAS and BRAF are key members of
this pathway, constitutively active due to oncogenic mutations in
,40% of human cancers, with a prevalence of mutation that
varies considerably among tumors originating from different
tissues [2]. KRAS oncogenic activation, largely due to codon 12–
13 mutations, occurs in ,40% of CRC [3,4] and in ,15% of
NSCLC [5]. As expected, KRAS mutations have been associated
with poor response to anti-EGFR therapy in patients with both
CRC [3] and NSCLC [6]. Wild type KRAS is now considered
a pre-condition to treat CRC patients with EGFR inhibitors like
Cetuximab or Panitumumab [7,8]. Oncogenic BRAF mutations
occur in up to 15% of all human tumors, the vast majority (.90%)
being c.1799:T.A substitutions that lead to the replacement of
valine with aspartic acid (V600E) causing constitutive BRAF
activation [9]. Melanoma (40–60%) [10] and papillary thyroid
carcinoma (PTC; 40%–80%) [11] are the tumors with the highest
incidence of BRAF mutations. While BRAF mutations are
uncommon in NSCLC [12], they occur in ,10–15% of CRC
and are strongly associated with non-Lynch microsatellite unstable
tumors and with the CpG island methylator phenotype [13].
Similar to KRAS, BRAF mutation has been correlated with lack of
response to EGFR inhibitors in patients with advanced CRC and
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currently being investigated [14]. Furthermore, novel BRAF
inhibitor molecules like vemurafenib are proving highly effective
to treat patients with BRAF mutated tumors, like melanoma [15].
Additional reasons for molecular testing are the diagnostic or
prognostic information that can be obtained by the analysis of
tumors with a high prevalence of specific mutations as is the case
for KRAS and pancreatic lesions [16] or BRAF and thyroid nodules
[11].
The above considerations point to the necessity to test for KRAS
and BRAF mutations. In fact, the advent of targeted therapy
mandates the analysis of large numbers of tumors and is forcing
the integration of molecular data into the routine workflow of
cancer patients [1]. This can prove a challenge and underlines the
importance of utilizing detection methods that are sensitive, rapid,
reproducible and cost-effective.
Sanger sequencing is highly reliable and currently considered
the ‘‘gold standard’’ technique for mutation detection [7,8].
However, when applied to routine diagnostic use suffers from
several limitations. Sanger sequencing is low throughput, requires
several distinct steps (e.g. PCR, amplicon purification, labelling)
each of which is exposed to contamination risk, is relatively
dependent on the quality and integrity of DNA, and has a low
analytical sensitivity, requiring at least 25% of mutated DNA-
corresponding to at least 50% of neoplastic cells with an
heterozygous mutated allele. Considering that many routine
samples contain large numbers of non-neoplastic reactive/
inflammatory cells, dissection of specimens prior to DNA
extraction is usually necessary to enrich for neoplastic cells and
to avoid false negative results. A variety of more sensitive methods
based on different approaches are utilized to overcome the
limitations of Sanger sequencing, but many of them can be time-
consuming, labor-intensive, expensive or require the use of
sophisticated platforms not always affordable by pathology
laboratories [17,18].
We here describe a new assay that we have called Allele Specific
Locked Nucleic Acid quantitative PCR (ASLNAqPCR) based on
39-locked nucleic acid (LNA)-modified primers and the use of
a LNA-modified beacon probe. The assay is very cost-effective and
not only identifies mutations with high specificity and sensitivity,
but unlike other methods gives reliable information about the ratio
of mutant and wild-type alleles. We have utilized ASLNAqPCR to
identify the most common codon 12 and 13 KRAS mutations and
the BRAF V600E mutation, but the test can be easily adapted to
detect hot spot mutations in other oncogenes.
Materials and Methods
Ethics Statement
Since KRAS and BRAF mutational analysis is part of proper
diagnostic protocols, the need for ethic committee’s approval was
not necessary for this study, in accordance with medical ethical
guidelines of the Azienda Unita’ Sanitaria Locale di Bologna
(Ufficio Qualita’ di Sistema Aziendale, Via Castiglione 29, 40100
Bologna). Accordingly to these guidelines, a comprehensive
written informed consent was signed for the surgical treatment
that produced the tissue samples and the related diagnostic
procedures. All information regarding the human material used in
this study was managed using anonymous numerical codes, clinical
data were not used and samples were handled in compliance with
the Helsinki declaration (http://www.wma.net/en/
30publications/10policies/b3/).
Selection of tumor material
Three hundred consecutive tumor samples from the De-
partment of Pathology of the Azienda Unita’ Sanitaria Locale di
Bologna Ospedale Bellaria-Universita ` di Bologna and correspond-
ing to 281 patients, were analyzed. Of the 300 samples, 220 were
primary tumours: 163 from the colon, 29 from the lung, 21 from
the pancreas-9 adenocarcinomas and 12 cyst fluid aspirates from
pancreatic neoplasms-and 7 from the thyroid. The remaining 80
samples were metastases at various sites from primary tumors of
the colon (n=71) or lung (n=9) (Table 1 and Table 2). Two
hundred and seventy-six samples were obtained from routinely
processed formalin-fixed paraffin embedded (FFPE) sections (187
surgical specimens, 89 biopsy samples); 21 were fine needle
cytology aspirates from pancreatic and 3 from lung lesions. For
FFPE material, Hematoxylin and Eosin (H&E) sections were
reviewed to identify paraffin blocks with the highest relative
amount of tumor vs. stroma, few infiltrating lymphocytes and little
or no tumor necrosis. Six 10 mm thick sections were cut from each
block, followed by one H&E control slide. The tumor area selected
for the analysis was marked on the control slide to ensure,
whenever possible, greater than 70% content of neoplastic cells, in
accordance with published guidelines [8]. Tumor material was
manually dissected under microscopic guidance from the corre-
sponding 10 mm sections using a sterile blade. Dissected tumor
areas ranged from 0.25–1.0 cm
2. For cytology preparations the
slides with the highest tumor content were selected and material
collected after removal of the coverslip. All patient information
was handled in accordance with review board approved protocols
and in compliance with the Helsinki declaration (http://www.
wma.net/en/30publications/10policies/b3/).
Cell line controls
The SW620 (KRAS G12V homozygous, ATCC – American
Type Culture Collection, Rockville, MD, USA), CAL62 (KRAS
G12R heterozygous), OCUT (BRAF V600E heterozygous), ARO
(BRAF V600E heterozygous) and TPC-1 (BRAF wild type,
American Type Culture Collection, Rockville, MD, USA) cell
lines were used as DNA controls for mutational analysis. The
CAL62, OCUT and ARO cell lines have been previously
described [19] and were kindly provided by Prof. M. Santoro
(University of Naples, Italy). Mutant DNA extracted from the cell
lines was spiked in a pool of healthy female donor DNA (DNA
Female pool, Cod. G1521, Promega, Madison WI) and serially
diluted as 50%, 20%, 10%, 5%, 1%, 0,1%, 0.01% mutant to wild
type DNA ratios to determine the analytical sensitivity of both
Sanger sequencing and ASLNAqPCR. The minimal amount of
input DNA required to obtain reliable mutation detection with the
ASLNAqPCR method was determined by serially diluting DNA of
the G12V mutated SW620 cell line with normal DNA, as
previously described [20].
Primers and molecular beacon probes design
Primers and molecular beacon probes for ASLNAqPCR were
designed using Primer3 software (http://frodo.wi.mit.edu/
primer3/) (Table 3). They identify the seven most common KRAS
mutations at codons 12 and 13, present in greater than 95% of
tumors with mutated KRAS [3] and the BRAF V600E present in
.90% of tumors with a BRAF mutation [9]. Forward ASL-
NAqPCR mutation-specific primers were modified with LNA
nucleotides [21] at the 39-end terminal of the oligonucleotide
sequence (Table 3 and Figure 1). Two internal LNA-modified
molecular beacon probes were designed, one for KRAS and one for
BRAF real-time analysis (Table 3 and Figure 1). Flanked molecular
beacon arms were designed using the OLIGO 6.0 software
ASLNAqPCR for KRAS/BRAF Mutation Detection
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conformation. All primers and probes were tested by MFOLD
(http://www.bioinfo.rpi.edu/applications/mfold/old/dna/) to
avoid secondary structures. Table 3 also shows the standard set
of primers for KRAS [3] and BRAF [22] used for Sanger
sequencing.
Mutational Analysis
DNA was extracted from FFPE using the RecoverAll kit
(Ambion, Austin TX, U.S.A.), according to the manufacturer’s
recommendation. DNA from cell lines and FNA samples was
extracted using the Gentra Puregene Kit (Qiagen, Hilden,
Germany). DNA concentration was measured using the Quant-
iT
TM dsDNA BR kit (Invitrogen, Carlsbad, CA).
a) Sanger Sequencing. All 300 samples were tested for
KRAS, 201 for BRAF. Exon 2 and 3 of KRAS and exon 15 of BRAF
were evaluated amplifying fragments of 264 bp, 257 bp, and
223 bp respectively, similar to what previously described [3,22].
PCR reactions were performed using the FastStartTaq DNA
polymerase (Roche Applied Science, Mannheim, Germany)
following the instructions of the provider, starting from 30–
50 ng for DNA from FFPE and from about 15 ng for cell line
DNA. The cycling conditions are shown in Table 4. Sequencing
was carried out according to standard procedures using the
GenomeLab DTCS Kit (Beckman Coulter, Inc., Fullerton, CA,
U.S.A.) and a CEQ2000 XL automatic DNA sequencer (Beckman
Coulter, Inc., Fullerton, CA, U.S.A). Strands were screened using
forward and reverse primers.
Table 1. KRAS mutations in 300 consecutive samples analyzed by Sanger sequencing and ASLNAqPCR.
Tissue KRAS No amplifiable DNA
Mutated by SSEQ (%) Mutated by ASLNA (%) SSEQ (%) ASLNA (%)
COLON CRC (n=234) 80/209 (38.3) 94/221 (44.8) 25/234 (10.7) 13/234 (5.6)
Primary (n=163) 56/146 (38.4) 69/153 (45.1) 17/163 (10.4) 10/163 (6.1)
Metastatic (n=71) 24/63 (38.1) 25/68 (36.7) 8/71 (11.3) 3/71 (4.2)
LUNG NSCLC (n=38) 16/38 (42.1) 17/37 (45.9) 0/38 (0) 1/38 (0)
Primary (n=29) 9/29 (31.0) 12/29 (41.4) 0/29 (0) 0/29 (0)
Metastatic (n=9) 7/9 (77.8) 5/8 (62.5) 0/9 (0) 1/9 (11.1)
PANCREAS (n=21) 7/21 (33.3) 6/21 (28.6) 0/21 (0) 0/21 (0)
Carcinoma (n=9) 4/9 (44.4) 4/9 (44.4) 0/9 (0) 0/9 (0)
Cyst Fluid (n=12) 3/12 (25.0) 2/12 (16.7) 0/12 (0) 0/12 (0)
THYROID (n=7) 0/6 (0) 0/7 (0) 1/7 (14.3) 0/7 (0)
PTC-Classic (n=3) 0/3 (0) 0/3 (0) 0/3 (0) 0/3 (0)
PTC-Others (n=4) 0/3 (0) 0/4 (0) 1/4 (25) 0/4 (0)
SSEQ, Sanger sequencing; ASLNA, allele specific quantitative PCR using 39-locked nucleic acid modified primers (ASLNAqPCR); CRC, colonic adenocarcinoma; NSCLC,
lung adenocarcinoma; PTC, papillary thyroid carcinoma.
doi:10.1371/journal.pone.0036084.t001
Table 2. BRAF mutations analysis in 201 consecutive samples analyzed by Sanger sequencing and ASLNAqPCR.
Tissue BRAF No amplifiable DNA
Mutated by SSEQ (%) Mutated by ASLNA (%) SSEQ (%) ASLNA (%)
COLON CRC (n=159) 15/153 (9.8) 19/153 (12.4) 6/159 (3.8) 6/159 (3.8)
Primary (n=114) 13/109 (11.9) 15/109 (13.8) 5/114 (4.4) 5/114 (4.4)
Metastatic (n=45) 2/44 (4.5) 4/44 (9.1) 1/45 (2.2) 1/45 (2.2)
LUNG NSCLC (n=24) 0/24 (0) 0/24 (0) 0/24 (0) 0/24 (0)
Primary (n=17) 0/17 (0) 0/17 (0) 0/17 (0) 0/7 (0)
Metastatic (n=7) 0/7 (0) 0/7 (0) 0/7 (0) 0/7 (0)
PANCREAS (n=11) 0/10 (0) 0/10 (0) 1/11 (9.1) 1/11 (9.1)
Carcinoma (n=5) 0/5 (0) 0/5 (0) 0/5 (0) 0/5 (0)
Cyst Fluid (n=6) 0/5 (0) 0/5 (0) 1/6 (16.7) 1/6 (16.7)
THYROID (n=7) 0/7 (0) 1/7 (1.4) 0/7 (0) 0/7 (0)
PTC-Classic (n=3) 0/3 (0) 1/3 (0) 0/3 (0) 0/3 (0)
PTC-Others (n=4) 0/4 (0) 0/4 (0) 0/3 (0) 0/3 (0)
SSEQ, Sanger sequencing; ASLNA, allele specific quantitative PCR using 39-locked nucleic acid modified primers (ASLNAqPCR); CRC, colonic adenocarcinoma; NSCLC,
lung adenocarcinoma; PTC, papillary thyroid carcinoma.
doi:10.1371/journal.pone.0036084.t002
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for BRAF. Fifteen nanograms of DNA purified from fresh cell lines,
or 15–50 ng of DNA purified from FFPE, were amplified using the
FastStart Universal Probe Master with ROX (Roche Applied
Science, Mannheim, Germany) in separate real time reactions for
each allele specific primer, but in the same run and following the
same cycling conditions shown in Table 4. PCR products were
117 bp for BRAF V600E and 104 to 110 bp for KRAS. Real-time
PCR was performed using an ABI SDS 7000TM instrument
(Applied Biosystems, Foster City, CA). The relative mutant allele
copy number was quantified during the exponential phase of real-
time PCR using the DCT method [23]. Samples with
Table 3. Primers and beacon probes.
Sanger Sequencing
Gene Exon Forward Primer Reverse Primer
KRAS 2 AAGGTGAGTTTGTATTAAAAGGTACTGG TGGTCCTGCACCAGTAATATGC
3 TCCAGACTGTGTTTCTCCCTTCTC AAAACTATAATTACTCCTTAATGTCAGCTT
BRAF 15 TCATAATGCTTGCTCTGATAGGA GGCCAAAAATTTAATCAGTGGA
ASLNAqPCR
Gene WT/Mutation Forward Primer Reverse Primer









BRAF WT TAGGTGATTTTGGTCTAGCTACAG+T TTAATCAGTGGAAAAATAGCCTCA
V600E TAGGTGATTTTGGTCTAGCTACAG+A TTAATCAGTGGAAAAATAGCCTCA
BEACON 59-FAM-CCGAAGGGGATC+CAGACAA+CTGTTCAAACTGCCTTCGG-3BHQ-1 -39
bp, base pair. ‘‘+’’ precedes LNA-modified nucleotides.
doi:10.1371/journal.pone.0036084.t003
Figure 1. Diagram illustrating ASLNAqPCR. Left side: a single mismatch of the LNA modified primer does not allow PCR amplification. Right
side: in case of a perfect match, the Taq polymerase extends the DNA strand and the amplicon is detected by the internal LNA modified beacon
probe.
doi:10.1371/journal.pone.0036084.g001
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considered failures and excluded from the study.
c) Pyrosequencing. Twenty-one samples with discrepant
results between Sanger sequencing and ASLNAqPCR were tested
by pyrosequencing, according to standard procedures using
PyroMark Gold Q96 (Qiagen, Gmbh, Hilden Germany)
reagents and a PyroMarkTM Q96 ID instrument. Pyrograms
outputs were analysed with PyroMarkTM Q96 ID Software
(Qiagen, Gmbh, Hilden Germany) using the allele quantification
(AQ) mode.
Statistical measures of performance. True positive (TP),
false positive (FP), true negative (TN), false negative (FN), test
sensitivity (SEN), specificity (SPEC), negative predictive value
(NPV), positive predictive value (PPV), accuracy (ACC), false
discovery rate (FDR) [24].
Results
Of the 300 consecutive cases, 201 were analyzed for both KRAS
and BRAF and 99 only for KRAS. Ten of 300 cases analyzed for
KRAS gave no amplifiable products due to excessive DNA
degradation with both Sanger sequencing and the ASLNAqPCR
technique. Sixteen additional cases gave amplifiable KRAS PCR
products by ASLNAqPCR but not by sequencing and four
additional cases by sequencing but not by ASLNAqPCR. Seven of
201 cases analyzed for BRAF gave no amplifiable products due to
excessive DNA degradation with both Sanger sequencing and
ASLNAqPCR.
ASLNAqPCR analytical sensitivity, intra– and inter-assay
reproducibility, failure rate
Analytical sensitivity-Sanger sequencing. Analytical
sensitivity was tested by serially diluting DNA from the G12V
mutated SW620 cell line, the G12R mutated CAL62 cell line, the
BRAF V600E mutated ARO cell line, the BRAF V600E mutated
OCUT cell line in a pool of healthy female donor DNA. The
TPC-1 cell line was used as non-mutated control for the dilution
tests. At least 20% of KRAS G12V and KRAS G12R DNA were
required to identify the mutations. The BRAF V600E mutation
was identified with at least 10% of mutated DNA.
Analytical sensitivity-ASLNAqPCR. Analytical sensitivity
was tested with the same mutated DNA dilutions used for the
Sanger sequencing. The KRAS G12V and KRAS G12R mutations
were reproducibly detectable at a dilution of 0.1% with a PCR
efficiency of 111.3% (slope: 23.0764, R
2: 0.9907) [23] (Figure 2).
The BRAF V600E mutation was reproducibly detected at
a dilution of 0.1% with a PCR efficiency of 116.2% (slope:
22.9854, R
2: 0.9908) [23] (Figure 3).
Minimal amount of input DNA for ASLNAqPCR at the
analytical sensitivity threshold. The amount of a 0.1%
dilution of KRAS G12V mutated SW620 cell line DNA and of
BRAF V600E mutated ARO cell line DNA spiked with normal
DNA was serially decreased to determine the minimal input DNA
necessary for mutation detection. A minimal amount of 6.25 ng of
DNA from cell lines (equivalent to ,1000 copies of a diploid
human genome) was necessary to detect both mutations.
ASLNAqPCR analysis of all clinical samples below the 6.25 ng
Table 4. PCR conditions for Sanger sequencing and ASLNAqPCR.
Sanger Sequencing
Amplicon Temperature Time Cycles
BRAF (Ex15) 95uC4 9 1
95uC3 0 0 40
53uC3 0 0 40
72uC3 0 0 40
72uC1 0 9 1
KRAS (Ex2 and Ex3)
a 95uC4 9 1
95uC3 0 9 5
63uC–1uC/cycle 309 5
72uC3 0 0 5
95uC3 0 0 35
58uC3 0 0 35
72uC3 0 0 35
72uC1 0 9 1
ASLNAqPCR
Amplicon Temperature Time Cycles
KRAS
b BRAF
c 50uC2 9 1
95uC1 0 9 1
95uC3 0 0 38
60uC* 300 38
72uC3 0 0 38
Ex, exon;
aFor KRAS amplification a touch-down PCR was performed;
bPCR for wild type KRAS and all 7 codon 12 and 13 mutations;
cPCR for wild type BRAF and BRAF
V600E; *Plate reading step.
doi:10.1371/journal.pone.0036084.t004
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PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e36084Figure 2. Standard curve titration of ASLNAqPCR for KRAS. Serial dilution of the KRAS G12V mutated SW620 cell line DNA in wild type DNA.
Gray squares correspond to 50%, 20%, 10%, 5%, 1%, 0,1%, 0.01% mutant to wild type DNA ratios (duplicate samples). The titration slope is 23.076, R
2
is 0.991 (top right), corresponding to a PCR efficiency of 111.3%.
doi:10.1371/journal.pone.0036084.g002
Figure 3. Standard curve titration of ASLNAqPCR for BRAF. Serial dilution of the BRAF V600E mutated OCUT cell line DNA in wild type DNA.
Gray squares correspond to 50%, 20%, 10%, 5%, 1%, 0,1%, 0.01% mutant to wild type DNA ratios (duplicate samples). The titration slope is 22.985, R
2
is 0.991 (top right), corresponding to a PCR efficiency of 116.2%.
doi:10.1371/journal.pone.0036084.g003
ASLNAqPCR for KRAS/BRAF Mutation Detection
PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e36084input DNA threshold was therefore repeated starting with a higher
amount of tumor tissue.
ASLNAqPCR intra– and inter-assay
reproducibility. Intra-assay reproducibility (i.e. the
consistency of results in the same run) has been measured by
calculating the Ct (cycle threshold) coefficients of variation of
samples run as duplicate in the same plate using serial dilution
(50%, 20%, 10%, 5%, 1%, 0,1%) of mutant DNA in wild type
DNA for KRAS (CAL62 and SW620 cell lines) and BRAF (ARO
and OCUT cell lines). The coefficients of variation for the KRAS
mutated DNA ranged between 0.08% and 1.03%. Those for the
BRAF mutated DNA ranged between 0.15% and 1.54%. Inter-
assay reproducibility (i.e. the consistency of results with the same
protocol but in different runs) has been similarly measured by
calculating the Ct coefficient of variation of duplicate samples run
in different days using the same serial dilutions of mutated DNA
mentioned above. The coefficients of variation for the KRAS
mutated DNA ranged between 0.91% and 1.62%. Those for the
BRAF mutated DNA ranged between 1.12% and 1.73%. Both
intra– and inter assay reproducibility results are well within the
10% range considered satisfactory [25].
ASLNAqPCR failure rate. The failure rate was tested by
repeating a series of samples with a mutated/wild type ratio thrice
the analytical sensitivity threshold, according to published
guidelines [26]. Twenty-four samples with a 0.3% dilution of
KRAS G12V SW620 cell line DNA and of BRAF V600E ARO cell
line DNA were tested. The failure rate was zero, as mutations were
consistently detected in all cases.
KRAS and BRAF mutation analysis
Sanger sequencing analysis. Two-hundred-seventy-four
samples gave amplifiable DNA and 103 of them (37.6%) showed
a KRAS mutation at codon 12, 13 or 61 (Table 1 and Table 5). Out
of these, five cases had mutations in exon 3 codon 61 (Q61H or
Q61L), not detectable by our ASLNAqPCR method. Fifteen out of
the 194 evaluable cases (7.7%) showed the BRAF V600E mutation
(Table 2 and Table 5). No BRAF exon 15 mutations other than the
V600E were detected. KRAS and BRAF mutations were mutually
exclusive on all cases.
ASLNAqPCR analysis. Two-hundred-eighty-six samples
gave amplifiable DNA and 117 of them (40.9%) showed a KRAS
mutation at codon 12, 13 (Table 1 and Table 5), codon 61
mutations were not tested by ASLNAqPCR. Twenty of the 194
evaluable cases (10.3%) showed the BRAF V600E mutation
(Table 2 and Table 5). No BRAF exon 15 mutations other than
the V600E were tested by ASLNAqPCR. Quantitative real time
data always indicated a mutant/wild type ratio equal to or less
than 1, consistent with heterozygous mutations. As in the case of
Sanger sequencing results, KRAS and BRAF mutations were always
mutually exclusive.
The KRAS and BRAF V600E mutation rates detected in our
series by both Sanger sequencing and ASLNAqPCR are
compatible with the data reported in the literature for colon
adenocarcinoma (Table 6) and the other tumors analyzed
[3,4,5,11,16,27].
Comparison between Sanger and ASLNAqPCR and
pyrosequencing of samples with discordant
results. Sanger sequencing and the ASLNAqPCR assay
generated discordant results in 22/300 samples for KRAS
mutations (7.3%) (Table 7) and in 5/201 samples for BRAF
V600E (2.5%) (Table 8). Eighteen discordant KRAS samples and 3
discordant BRAF ones were further analyzed by pyrosequencing.
No additional material was available to repeat the test in 4 KRAS
and 2 BRAF mutated cases. Among the samples re-tested by
pyrosequencing there were two mutated for KRAS Q61H and one
for KRAS G12F, not detectable by ASLNAqPCR. Pyrosequencing
confirmed all KRAS mutations identified by ASLNAqPCR but not
detected by Sanger sequencing (Table 7, Figure 4). Importantly,
quantitative real time data showed a mutated/wild type ratio
#10% –below our KRAS Sanger sequencing analytical sensitivity
Table 5. Frequence of specific KRAS and BRAF mutations
cases analyzed by SSEQ and ASLNAqPCR.
Gene Mutation SSEQ (%) ASLNA (%)
KRAS
(n=300)
G12D 41/274 (14.9) 48/286 (16.8)
G12V 23/274 (8.4) 26/286 (9.1)
G13D 17/274 (6.2) 19/286 (6.6)
G12C 8/274 (2.9) 12/286 (4.2)
G12S 3/274 (1.1) 4/286 (1.4)
G12A 3/274 (1.1) 3/286 (1.1)
G12R 2/274 (0.7) 5/286 (1.7)
G12F 1/274 (0.4) NT
Q61H 3/274 (1.1) NT
Q61L 2/274 (0.7) NT
All mutant cases 103/274 (37.6) 117/286 (40.9)
No amplifiable DNA 26/300 (8.7) 14/300 (4.7)
BRAF
(n=201)
V600E 15/194 (7.7) 20/194 (10.3)
No amplifiable DNA 7/201 (3.5) 7/201 (3.5)
SSEQ, Sanger sequencing; ASLNA, allele specific quantitative PCR using 39-
locked nucleic acid modified primers (ASLNAqPCR); NT, not tested, since
ASLNAqPCR primers were designed to identify only the seven most common
codon 12213 KRAS mutations.
doi:10.1371/journal.pone.0036084.t005
Table 6. KRAS mutations in primary colon carcinoma (n=163)
compared with data reported in the literature




G12D 22/146 (15.1) 27/153 (17.7) 12.9–15.5
G12V 14/146 (9.6) 15/153 (9.8) 7.7–12.2
G13D 8/146 (5.5) 10/153 (6.5) 5–7.3
G12C 5/146 (3.4) 7/153 (4.4) 2.323.6
G12A 3/146 (2.1) 3/153 (2.0) 2.3–2.8
G12S 3/146 (2.1) 4/153 (2.6) 2.6–4.3
G12R 0/146 (0) 3/153 (2.0) 0.3–0.5
G12F 1/146 (0.7) NT 0.2
Q61H 0/146 (/) NT 0.1
Q61L 0/146 (/) NT 0.1
All mutant cases 56/146 (38.4) 69/153 (45.1) 37–42.6
No amplifiable
DNA
17/163 (10.4) 10/163 (6.1) ___
ASLNA, allele specific quantitative PCR using 39-locked nucleic acid modified
primers (ASLNAqPCR); NT, not tested, since ASLNAqPCR primers were designed
to identify only the seven most common codon 12–13 KRAS mutations.
a References [Bamford et al., 2004; Karapetis et al., 2008; Neumann et al., 2009].
doi:10.1371/journal.pone.0036084.t006
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BRAF real time data (Table 8, Figure 5). Review of the pathology
material showed variable ratios of tumor to non-neoplastic cells in
the areas that were manually dissected for mutational analysis
where a mutation was detected by ASLNAqPCR, confirmed by
pyrosequencing but not identified by Sanger sequencing. In the
majority of samples the discrepant result was simply explained by
the low tumor to non-neoplastic cell ratio and the higher analytical
sensitivity of ASLNAqPCR (Figure 6, panels A and B). However,
in some samples tumor heterogeneity was a contributing factor.
ASLNAqPCR quantification of the mutated to wild type allele
ratio clearly indicated the presence of tumor cell subclones in 7 of
the 16 discrepant KRAS results (cases 1, 8, 9, 10, 11, 12, 16 of
Table 7, Figure 6, panels C and D) and in 3 of the 5 discrepant
BRAF results (cases 2, 3, 4 of Table 8). In these cases,
ASLNAqPCR results and review of the tumor to non-neoplastic
cell ratio in the area dissected for DNA extraction were consistent
with mutated cells representing ,30% of the tumor cell
population, assuming that all mutations were heterozygous. In
two cases data indicated that mutated cells represented ,5% of
the tumor (case 1 of Table 7 and case 2 of Table 8, Figure 6,
panels C and D).
The only cases mutated by Sanger sequencing and pyrosequen-
cing for which a mutation was not identified by ASLNAqPCR
were two cases with KRAS Q61H (cases 18 and 19 of Table 7), not
tested by our ASLNAqPCR primers. In one additional case with
a G12F (case 17 of Table 7) the Glycine to Phenylalanine
mutation was due to a double nucleotide substitution from GGT
to TTT on the same KRAS allele, as confirmed by pyrosequencing.
The case was identified as mutated by the ASLNAqPCR primer
specific for the Glycine to Cysteine mutation (G12C). This is due
to the fact that the G12C specific primer correctly recognized the
mutated Thymine at the first nucleotide position of the codon. The
primer specific for G12V, that recognizes mutated thymines at the
second position, was not able to anneal due to the presence,
instead of the wild type Guanine, of the mutated Thymine at the
beginning of the codon.
Statistical measures of performance
Test sensitivity, specificity and other statistical measures of
performance for ASLNAqPCR and Sanger sequencing are shown
in Table 9. We considered a result true positive (TP), false positive
(FP), true negative (TN) or false negative (FN) as follows. TP were












1 WT G12D 1.5 G12D CRC, resection 70
2 WT G12C 3.0 G12C NSCLC, biopsy 10
3 WT G12D 8.0 G12D CRC, resection 35
4 WT G12R 4.0 G12R CRC, resection 15
5 WT G12R 4.0 G12R CRC, resection 25
6 WT G12S 8.0 G12S CRC, resection 30
7 WT G12C 7.0 G12C CRC, resection 45
8 WT G12V 5.0 G12V CRC, resection 70
9 WT G13D 7.0 G13D CRC, resection 70
10 WT G12D 6.0 G12D CRC, resection 45
11 WT G12D 2.0 G12D NSCLC, biopsy 30
12 WT G13D 3.0 G13D CRC, resection 35
13 WT G12V 4.0 G12V CRC, resection
c 10
14 WT G12D 1.0 G12D PC, FNA ,5
15 WT G12C 3.0 G12C NSCLC, biopsy 5
16 WT G12V 10.0 NP CRC, resection 80
17 G12F G12C 20.0 G12F CRC, resection 45
18 Q61H WT / Q61H metNSCLC, LN
biopsy
50
19 Q61H WT / Q61H PC, FNA 60
20 Q61H WT / NP metCRC, liver
biopsy
70
21 Q61L WT / NP metCRC, lung
biopsy
50
22 Q61L WT / NP PC, FNA 40
SSEQ, Sanger sequencing; ASLNA, allele specific quantitative PCR using 39-locked nucleic acid modified primers (ASLNAqPCR); WT, wild type; NP, not performed due to
lack of additional DNA; CRC, colonic adenocarcinoma; NSCLC, lung adenocarcinoma; met, metastatic; LN, lymph node; FNA, fine needle aspirate; PC, pancreatic
carcinoma.
aASLNAqPCR primers designed to identify only the seven most common codon 12–13 KRAS mutations, codon 61 KRAS and G12F mutations are not
detectable.
bReal time ASLNAqPCR quantitative data.
cStatus post neoadjuvant chemo– and radiation therapy.
dPercentage of the tumor/non neoplastic cells ratio
estimated in the area dissected for DNA extraction.
doi:10.1371/journal.pone.0036084.t007
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and ASLNAqPCR; for cases that gave a discrepant results by the
two methods, we considered true positives those with the mutation
confirmed by pyrosequencing. FP were cases where a mutation
found by one of the two methods (Sanger or ASLNAqPCR) was
not confirmed by pyrosequencing. TN were cases that resulted
wild type by both Sanger sequencing and ASLNAqPCR; for cases
that gave a discrepant results by the two methods, we considered
true negatives those that resulted wild type by pyrosequencing. FN
were cases where a wild type result by one of the two methods
(Sanger or ASLNAqPCR) resulted mutated by pyrosequencing.
Test sensitivity (SEN), specificity (SPEC), negative predictive value
(NPV), positive predictive value (PPV), accuracy (ACC) and false
discovery rate (FDR) were calculated as follows: SEN = TP/
(TP+FN); SPEC = TN/(TN+FP) 6100; NPV = TN/(TN+FN)
6100; ACC = (TP+TN)/(TP+FP+TN+FN) 6100; FDR = FP/
(FP+VP). Our ASLNAqPCR was designed to detect the seven
most common codon 12–13 KRAS mutations and did not detect
codon 61 KRAS mutations. For statistical evaluation, all mutations
not detected by ASLNAqPCR, including those for which allele
specific primers were not designed, were scored as ASLNAqPCR
‘‘wild type’’ results. As shown in Table 9, ASLNAqPCR had 100%
specificity, as did Sanger sequencing. The sensitivity of ASL-
NAqPCR was 95.19%, higher than that of Sanger sequencing
(81.37%). Also accuracy and negative predictive value were
greater for ASLNAqPCR compared with Sanger sequencing.














1 WT V600E 1.25 V600E metCRC, LN biopsy 5
2 WT V600E 1.25 V600E CRC, resection, 75
3 WT V600E 1.5 V600E CRC, resection 55
4 WT V600E 3.0 NP PTC, resection 80
5 WT V600E 3.0 NP CRC, resection 10
SSEQ, Sanger sequencing; ASLNA, allele specific quantitative PCR using 39-locked nucleic acid modified primers (ASLNAqPCR); WT, wild type; NP, not performed due to
lack of additional DNA; CRC, colonic adenocarcinoma; met, metastatic; LN, lymph node; PTC papillary thyroid carcinoma.
aASLNAqPCR primers designed to identify only
the BRAF V600E mutation.
bReal time ASLNAqPCR quantitative data.
cPercentage of the tumor/non neoplastic cells ratio estimated in the area dissected for DNA
extraction.
doi:10.1371/journal.pone.0036084.t008
Figure 4. ASLNAqPCR and corresponding Sanger sequencing of four representative tumor samples analyzed for KRAS mutations.
Sample A is wild type, samples B, C and D are KRAS G12D mutated with varying amounts of tumor vs. non neoplastic cells; assuming that KRAS G12D
is heterozygous, quantitation of mutated DNA by ASLNAqPCR (DCT method) is consistent with 70% of mutated cells in sample B, 40% of mutated
cells in sample C, 4% of mutated cells in sample D; in sample D the KRAS G12D mutation is detected only by the ASLNAQPCR due to its high analytical
sensitivity.
doi:10.1371/journal.pone.0036084.g004
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The therapeutic use of tyrosine kinase receptors inhibitors
(TKIs), like Cetuximab or Panitumumab for CRC and Gefitinib
or Erlotinib for NSCLC that target EGFR, requires testing of the
molecular effectors downstream to the membrane-bound tyrosine
kinases and wild type status for these effectors is expected for
response to TKIs therapy. Among these, KRAS and BRAF are
commonly mutated and the absence of KRAS activating mutations
is now a necessary condition to treat CRC patients with
Cetuximab or Panitumumab. The need to screen for mutations
in a large number of patient samples with rapid turnaround time is
a strong motivation to develop methods that are cost-effective,
reliable and robust.
Our ASLNAqPCR is a novel allele specific assay with forward
mutation-specific primers modified with LNA nucleotides at the
39-end sequence terminal and an internal LNA-modified beacon
probe that detects and quantifies oncogenic mutations with high
specificity and sensitivity. Allele specific PCR is ideally suited to
detect oncogenic mutations when these are caused by relatively
few nucleotide changes at specific hot spots of the gene. However,
natural DNA primers in conventional allele specific PCR can miss-
anneal the target sequence, particularly when PCR conditions are
suboptimal (e.g. due to DNA damaged by formalin fixation or
degraded, limiting amounts of the target sequence), thus causing
false positive results that may have unwanted consequences for
TKI patient treatment.
LNAs are nucleic acid analogs with a 29-O, 49-C methylene
bridge that ‘‘locks’’ the ribose into a C39-endo conformation.
When LNA-modified nucleotides are incorporated in oligonucleo-
tides the melting DNA heteroduplex temperature (Tm) increases
between 1–8uC per LNA-modified nucleotide [21]. Because of the
increased Tm, LNA-modified nucleotides have been used for
a variety of applications, including in situ hybridization [28],
whole genome amplification [29], methylation sensitive PCR [20],
germline SNP genotyping [21], as blocker oligonucleotides to
suppress wild-type alleles and increase PCR sensitivity. Blocker
LNA oligonucleotides have been shown to be particularly useful to
detect oncogene mutations with high sensitivity, including KRAS
and BRAF [30]. We tested allele specific primers made of
unmodified DNA, but with the same base sequence shown in
Table 3 for KRAS and BRAF, observing a consistent reduction in
PCR specificity compared with the corresponding LNA-modified
primers. When performing Allele Specific PCR without LNA
modified primers we had false positive results in non-neoplastic
samples, including DNA extracted from peripheral blood
leukocytes. Specifically, four DNA samples from healthy blood
donors and a pool of healthy female donor DNA tested with Allele
Specific PCR showed bands compatible with KRAS and BRAF
mutations on the agarose gel. The same samples were wild type
when tested using ASLNAqPCR with LNA modified primers and
probe and after Sanger sequencing (data not shown). In fact, LNA
modification has been shown to greatly enhance allelic specificity,
while maintaining a high level of sensitivity in comparison with
conventional unmodified, natural DNA primers [21].
We have validated ASLNAqPCR analyzing 300 consecutive
samples of routinely processed CRC, NSCLC, pancreatic and
thyroid tumors, including both primary and metastatic lesions,
surgical specimens, biopsy samples and cytology preparations.
ASLNAqPCR identified KRAS and BRAF mutations with rates
comparable to those reported in the literature. The test was
‘‘robust’’ with excellent intra– and inter-assay reproducibility and
with only few routine samples that gave no amplifiable PCR.
There were no ASLNAqPCR failures after repeated testing of
a limiting ratio of KRAS and BRAF mutated cell line DNA/wild
type DNA. ASLNAqPCR was performed in parallel with
Figure 5. ASLNAqPCR and corresponding Sanger sequencing of four representative tumor samples analyzed for the BRAF V600E
mutation. Sample A is wild type, samples B, C and D are BRAF V600E mutated with varying amounts of tumor vs. non neoplastic cells; assuming that
BRAF V600E is heterozygous, quantitation of mutated DNA by ASLNAqPCR (DCT method) is consistent with 75% of mutated cells in sample B, 30% of
mutated cells in sample C, 3% of mutated cells in sample D; in sample D the BRAF V600E mutation is detected only by the ASLNAQPCR due to its high
analytical sensitivity.
doi:10.1371/journal.pone.0036084.g005
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compared, and discrepant cases analyzed by pyrosequencing to
statistically measure the performance of the assay. Our data
demonstrate that ASLNAqPCR has 100% specificity and positive
predictive value, with higher sensitivity, negative predictive value
and accuracy compared with Sanger sequencing. We observed no
false positive results, although if qPCR conditions are pushed
above 40 cycles false positive results may be expected [21].
The only mutated samples identified by Sanger sequencing and
confirmed by pyrosequencying, but not detected by ASL-
NAqPCR, were two KRAS Q61H mutations. One additional case
had a rare double nucleotide substitution at KRAS codon 12 that
ASLNAqPCR recognized as mutated but with the wrong
aminoacid call. None of these could be identified because our
allele specific primers were not designed to cover all possible codon
12 and 13 KRAS mutations, but only the most frequent, and we did
not design primers for codon 61 KRAS mutations. A limitation of
ASLNAqPCR, common to all hot spot mutation assays, is that it
identifies – by definition – only the targeted mutation, while
Sanger sequencing can identify all mutations present in the PCR
amplicon. Had our study been limited to codon 12 and 13 KRAS
mutations, ASLNAqPCR would have been ,100% sensitive. The
way ASLNAqPCR is designed allows for the easy addition of other
RAS allele specific primers. In fact, the test can be conveniently
adapted to identify hot spot mutations in other genes and we have
successfully utilized ASLNAqPCR to identify IDH1-R132H
mutation with high specificity and sensitivity in a series of more
than 100 gliomas (data not shown).
In all cases where KRAS or BRAF mutations were detected by
ASLNAqPCR, but not by Sanger sequencing, this was due to the
higher analytical sensitivity of the assay. ASLNAqPCR assay can
identify point mutations against a large excess of wild-type allele,
in the thousand-fold range. We detected 0.1% KRAS and 0.1%
BRAF mutated cell line DNA with high PCR efficiency, even when
DNA for mutational analysis was as little as 6.25 ng, the minimal
amount of input DNA at the analytical sensitivity threshold of the
method. The ASLNAqPCR analytical sensitivity is thus much
higher than that of conventional Sanger sequencing (,25%
Figure 6. KRAS mutations identified by ASLNAqPCR but not by Sanger sequencing. A, Hematoxylin and Eosin (H&E) stained section (X100)
of the area of case 13 of Table 7 (rectal adenocarcinoma treated with preoperative chemo– and radiation therapy) dissected for DNA extraction with
a tumor vs. non neoplastic cell ratio of ,10%, below the analytical sensitivity threshold of Sanger sequencing. B, ASLNAqPCR of case 13 of Table 7
shows a KRAS G12V mutation with a mutated/wild type ratio of 4%, corresponding to 8% mutated cells, assuming that the mutation is heterozygous;
this is consistent with the mutation being present in the large majority of neoplastic cells. C, H&E stained section (X100) of the area of the colonic
adenocarcinoma case 1 of Table 7, dissected for DNA extraction with a tumor vs. non neoplastic cell ratio of ,70%. D, ASLNAqPCR of case 1 of Table 7
shows a KRAS G12D mutation with a mutated/wild type ratio of 1.5%, corresponding to 3% mutated cells, assuming that the mutation is
heterozygous; this is consistent with a small KRAS G12D mutated subclone corresponding to ,4% of the neoplastic cells.
doi:10.1371/journal.pone.0036084.g006
Table 9. Statistical measures of performance for Sanger
sequencing and ASLNAqPCR.
Diagnostic
Test Specificity Sensitivity PPV NPV ACC FDR
SSEQ 100% 81.4% 100% 90.0% 94.2% 0
ASLNA 100% 95.2% 100% 97.0% 98.2% 0
SSEQ, Sanger sequencing; ASLNA, allele specific quantitative PCR using 39-
locked nucleic acid modified primers (ASLNAqPCR); PPV, positive predictive
value; NPV, negative predictive value; ACC, accuracy; FDR, false discovery rate.
doi:10.1371/journal.pone.0036084.t009
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methods such as pyrosequencing (1.25–2.5% mutated DNA) or
ARMS PCR with scorpion oligonucleotides (TheraScreen) (1.25%
mutated DNA) [31]. ASLNAqPCR is therefore ideally suited to
confidently detect mutations in samples were the abundance of
inflammatory cells, fibroblasts lymphocytes or other stromal
elements results in tumor to non-neoplastic cell ratios that are
below the recommended Sanger sequencing threshold of 50%
tumor cells – corresponding to 25% DNA with heterozygous
mutations [7]. In many of these samples the proportion of tumor
cells cannot be effectively enriched by manual dissection. This is
a common occurrence when the only material available for testing
are metastatic deposits in lymph nodes, samples from patients that
have undergone preoperatory chemo– and radiation treatment
and fine needle aspiration specimens [30]. On the other hand,
when tumor cells are abundant, the use of ASLNAqPCR makes
the dissection of tumor material unnecessary, thus obviating the
need for a laborious step that is time consuming and increases the
potential for sample contamination.
One relevant feature of ASLNAqPCR compared with tests
currently utilized to detect oncogenic mutations is that it allows for
precise quantification of the mutated allele due to the LNA-
modified beacon probe used for real time analysis. This is
important when a method with high analytical sensitivity is
utilized, since comparison of quantitative mutational data with the
proportion of tumor cells in the samples analyzed allows to easily
discriminate those where the mutation is widespread from those
where the mutation is present only in small neoplastic cell clones.
This was clearly the case in a few of our specimens, including both
colorectal and lung adenocarcinomas, where quantitative ASL-
NAqPCR results of KRAS and BRAF analysis showed that
mutations were present in a minority of the tumor cells. Although
our data do not indicate that this is a particularly common
occurrence, the presence of mutated subclones can be an issue for
individual cases. Had the DNA from these patients been analyzed
with a method that has high analytical sensitivity (e.g. pyrosequen-
cing), but that does not allow precise quantification of the mutated
allele, the tumors would have been diagnosed as mutated. This
can, at least in the case of KRAS, deny a potentially beneficial
treatment to CRC patients whose response to TKI may not be
affected by the presence of small mutated clones. On the other
hand, Sanger sequencing would have scored the case as negative
and failed to predict a possible limited response to TKI. Since
tumors are not always made of homogeneous cell populations,
their heterogeneity is a relevant concern for therapies that have
specific molecular targets. It is currently unclear if and how the
presence of small clones with DNA mutations affects the clinical
response to molecular inhibitors of oncogenic pathways [32,33].
The presence and successive selection of mutated clones may
indeed explain response failures in some patients [34]. Although
the impact of tumor heterogeneity in deciding patient manage-
ment is a matter of debate, quantitative mutational data may help
to clarify the issue, while providing the oncologist with accurate
data to manage the patient.
In addition to quantifying the mutation, ASLNAqPCR has
considerable practical advantages over other currently used
methods. The assay can be performed in any laboratory with
real-time PCR equipment, LNA-modified primers and probes can
be easily obtained at low cost and no proprietary reagents, other
than those for TaqMan chemistry, are necessary. Once DNA has
been extracted, few steps are required for the analysis. All
reactions, seven for the KRAS mutations and one for KRAS wild
type, one for BRAF V600E and one for BRAF wild type, have been
optimized for a single real time run with identical cycling
conditions. The entire procedure can be completed in ,3 hours,
including ,30 minutes operator time to load a 96 well plate,
,1 hour and 309 for the real-time run and ,109 for data analysis.
The short time for the analysis makes it possible to perform several
runs in the same day. In addition, since samples are analysed in
real-time there is no post-PCR manipulation, avoiding any risk of
carry-over contamination.
In summary, we report and validate ASLNAqPCR. The test is
rapid, cost-effective, highly sensitive and can accurately quantify
oncogenic mutations. It can be proposed as a method of choice to
analyze those samples that can not be enriched in neoplastic cell
content by tumor dissection prior to DNA extraction. We
validated the assay with primers designed to detect the most
common KRAS and BRAF mutations in routinely processed
samples, but ASLNAqPCR can easily be adapted to detect hot
spot mutations in other oncogenes.
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